Denosumab
R Rizzoli, U Yasothan, P Kirkpatrick - Nature Reviews Drug Discovery, 2010 - go.gale.com
R Rizzoli, U Yasothan, P Kirkpatrick
Nature Reviews Drug Discovery, 2010•go.gale.comIn May 2010, denosumab (Prolia; Amgen) was granted marketing authorization by the
European Commission for the treatment of postmenopausal women with osteoporosis who
are at increased risk of fracture, and for the treatment of bone loss associated with hormone
ablation therapy in men with prostate cancer at increased risk of fracture. Shortly after, in
June 2010, denosumab was approved by the US FDA for the treatment of postmenopausal
women with osteoporosis at high risk of fracture.Fractures owing to skeletal disorders …
European Commission for the treatment of postmenopausal women with osteoporosis who
are at increased risk of fracture, and for the treatment of bone loss associated with hormone
ablation therapy in men with prostate cancer at increased risk of fracture. Shortly after, in
June 2010, denosumab was approved by the US FDA for the treatment of postmenopausal
women with osteoporosis at high risk of fracture.Fractures owing to skeletal disorders …
In May 2010, denosumab (Prolia; Amgen) was granted marketing authorization by the European Commission for the treatment of postmenopausal women with osteoporosis who are at increased risk of fracture, and for the treatment of bone loss associated with hormone ablation therapy in men with prostate cancer at increased risk of fracture. Shortly after, in June 2010, denosumab was approved by the US FDA for the treatment of postmenopausal women with osteoporosis at high risk of fracture.
Fractures owing to skeletal disorders characterized by reduced bone strength, such as osteoporosis, are a major cause of disability, and contribute substantially to health-care costs.(1) The risk of osteoporotic fractures increases with age, particularly in postmenopausal women, in part owing to associated changes in levels of hormones that have a key role in the regulation of bone metabolism.(1, 2) Patients receiving hormone-ablation therapy for cancer also have an increased risk of fractures.(3)
Gale